Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach
Mem. Inst. Oswaldo Cruz
; 115: e200179, 2020. graf
Article
en En
| LILACS, SES-SP
| ID: biblio-1135266
Biblioteca responsable:
BR1.1
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results.
Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Inhibidores de Proteasas
/
Proteínas no Estructurales Virales
/
Betacoronavirus
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Mem. Inst. Oswaldo Cruz
Asunto de la revista:
MEDICINA TROPICAL
/
PARASITOLOGIA
Año:
2020
Tipo del documento:
Article